Drug Metabolism/Transport and Pharmacokinetics
This book serves to highlight the pharmacokinetics/drug–drug interactions and mechanistic understanding in relation to the drug-metabolizing enzymes and drug transporters.This book presents a series of drug metabolism and transport mechanisms that govern the pharmacokinetic features of therapeutic d...
Saved in:
| Sonstige: | |
|---|---|
| Year of Publication: | 2021 |
| Language: | English |
| Physical Description: | 1 electronic resource (232 p.) |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| LEADER | 04454nam-a2201273z--4500 | ||
|---|---|---|---|
| 001 | 993545965404498 | ||
| 005 | 20231214133354.0 | ||
| 006 | m o d | ||
| 007 | cr|mn|---annan | ||
| 008 | 202201s2021 xx |||||o ||| 0|eng d | ||
| 035 | |a (CKB)5400000000045325 | ||
| 035 | |a (oapen)https://directory.doabooks.org/handle/20.500.12854/77070 | ||
| 035 | |a (EXLCZ)995400000000045325 | ||
| 041 | 0 | |a eng | |
| 100 | 1 | |a Song, Im-Sook |4 edt | |
| 245 | 1 | 0 | |a Drug Metabolism/Transport and Pharmacokinetics |
| 260 | |a Basel, Switzerland |b MDPI - Multidisciplinary Digital Publishing Institute |c 2021 | ||
| 300 | |a 1 electronic resource (232 p.) | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 520 | |a This book serves to highlight the pharmacokinetics/drug–drug interactions and mechanistic understanding in relation to the drug-metabolizing enzymes and drug transporters.This book presents a series of drug metabolism and transport mechanisms that govern the pharmacokinetic features of therapeutic drugs as well as natural herbal medicines. It also covers the pharmacokinetic interactions caused by inhibiting or inducing the metabolic or transport activities under disease states or the coadministration of potential inhibitors. It also deals with microenvironmental pharmacokinetic profiles as well as population pharmacokinetics, which gives new insights regarding the pharmacokinetic features with regard to drug metabolism and transporters. | ||
| 546 | |a English | ||
| 650 | 7 | |a Medicine |2 bicssc | |
| 650 | 7 | |a Pharmaceutical industries |2 bicssc | |
| 653 | |a tofacitinib | ||
| 653 | |a dose-dependent pharmacokinetics | ||
| 653 | |a hepatic and intestinal first-pass effect | ||
| 653 | |a rats | ||
| 653 | |a catalposide | ||
| 653 | |a in vitro human metabolism | ||
| 653 | |a UDP-glucuronosyltransferase | ||
| 653 | |a sulfotransferase | ||
| 653 | |a carboxylesterase | ||
| 653 | |a celecoxib | ||
| 653 | |a drug–drug interaction | ||
| 653 | |a fluorescence | ||
| 653 | |a HPLC | ||
| 653 | |a metabolism | ||
| 653 | |a repaglinide | ||
| 653 | |a HSG4112 | ||
| 653 | |a anti-obesity agent | ||
| 653 | |a stereoselectivity | ||
| 653 | |a pharmacokinetics | ||
| 653 | |a compound K | ||
| 653 | |a protopanaxadiol (PPD) | ||
| 653 | |a biliary excretion | ||
| 653 | |a intestinal metabolism | ||
| 653 | |a Carthamus tinctorius extract | ||
| 653 | |a notoginseng total saponins | ||
| 653 | |a comparative pharmacokinetic study | ||
| 653 | |a large volume direct injection | ||
| 653 | |a compatibility mechanism | ||
| 653 | |a mertansine | ||
| 653 | |a human hepatocytes | ||
| 653 | |a cytochrome P450 | ||
| 653 | |a UDP-glucuronosyltransferases | ||
| 653 | |a sodium-glucose cotransporter 2 (SGLT2) inhibitors | ||
| 653 | |a DWP16001 | ||
| 653 | |a kidney distribution | ||
| 653 | |a inhibition mode | ||
| 653 | |a diabetes | ||
| 653 | |a transporter-enzyme interplay | ||
| 653 | |a influx transporter | ||
| 653 | |a efflux transporter | ||
| 653 | |a physiologically based pharmacokinetic model | ||
| 653 | |a cytochrome P450 enzymes | ||
| 653 | |a tiropramide | ||
| 653 | |a healthy Korean subjects | ||
| 653 | |a modeling | ||
| 653 | |a population pharmacokinetic | ||
| 653 | |a quercetin | ||
| 653 | |a breast cancer resistance protein | ||
| 653 | |a inhibitor | ||
| 653 | |a prazosin | ||
| 653 | |a sulfasalazine | ||
| 653 | |a kinetic analysis | ||
| 653 | |a food–drug interactions | ||
| 653 | |a Caco-2 | ||
| 653 | |a EpiIntestinal | ||
| 653 | |a first-pass | ||
| 653 | |a P-gp | ||
| 653 | |a BCRP | ||
| 653 | |a drug transporter | ||
| 653 | |a CYP3A4 | ||
| 653 | |a oral availability | ||
| 653 | |a automatization | ||
| 653 | |a drug absorption | ||
| 653 | |a drug dosing | ||
| 653 | |a head-and-neck cancer | ||
| 653 | |a real-time measurements | ||
| 653 | |a taxanes | ||
| 653 | |a tissue engineering | ||
| 653 | |a UHPLC-MS/MS | ||
| 653 | |a metformin | ||
| 653 | |a verapamil | ||
| 653 | |a drug interaction | ||
| 653 | |a organic cation transporter 2 | ||
| 653 | |a renal excretion | ||
| 653 | |a acute renal failure | ||
| 653 | |a gentamicin | ||
| 653 | |a cisplatin | ||
| 653 | |a hepatic CYP3A1(23) | ||
| 653 | |a creatinine clearance | ||
| 653 | |a renal clearance | ||
| 653 | |a nonrenal clearance | ||
| 776 | |z 3-0365-2459-2 | ||
| 776 | |z 3-0365-2458-4 | ||
| 700 | 1 | |a Song, Im-Sook |4 oth | |
| 906 | |a BOOK | ||
| ADM | |b 2023-12-15 05:51:59 Europe/Vienna |f system |c marc21 |a 2022-04-04 09:22:53 Europe/Vienna |g false | ||
| AVE | |i DOAB Directory of Open Access Books |P DOAB Directory of Open Access Books |x https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5338082170004498&Force_direct=true |Z 5338082170004498 |b Available |8 5338082170004498 | ||